High-risk percutaneous coronary intervention reflects a multitude of patient, anatomic, and procedural characteristics that can increase risk. The relative inability to withstand the hemodynamic sequelae of ischemia, arrhythmia, reperfusion injury, or distal embolization of plaque serves as a common foundation for this patient cohort. This enhanced susceptibility to circulatory collapse has stimulated the development and use of the intra-aortic balloon pump, Impella, TandemHeart, and extracorporeal membrane oxygenation. The authors discuss the physiology underpinning their application. Thereafter, they appraise the evidence base investigating their use in high-risk coronary intervention to determine which patients might benefit most from their use. CTO PCI was associated with lower procedural success (59% vs. 96%, p < 0.001) and higher major adverse cardiac event (1.6% vs. 0.8%, p < 0.001) rates. Multivariable analyses revealed several characteristics (older age, current smoking, previous myocardial infarction, previous coronary artery bypass graft, previous peripheral arterial disease, previous cardiac arrest, right coronary artery CTO target vessel, and less operator experience) associated with a lower likelihood of CTO PCI procedural success. as a therapeutic adjunct to support the heart during myocardial ischemia. However, mechanisms remain unclear. This study was therefore undertaken to provide some mechanistic insights into GLP-1-related cardioprotection. Specifically, the authors sought to determine whether pre-treatment with intravenous GLP-1(7-36) amide, commenced before an ischemic insult, protected the heart during percutaneous coronary intervention and whether it was associated with changes in the myocardial use of glucose. Inter-core lab variability in quantitative coronary angiography analysis of bifurcation lesions between 2 core labs was evaluated before and after alignment of the used methodology. Before alignment, the mean difference between the core labs (bias) was large for all quantitative coronary angiography parameters with wide 95% limits of agreement. The bias of the in-segment percentage diameter stenosis of the side branch was 5.5% (95% limits of agreement: -26.7% to 37.8%). After reanalysis, the bias of the in-segment percentage diameter stenosis of the side branch reduced to 1.8% (95% limits of agreement: -16.7% to 20.4%). These findings emphasize the importance of using the same methodology among different core labs worldwide.
The multicenter CT-RECTOR (Computed Tomography Registry of Chronic Total Occlusion
Revascularization) is a registry based on 240 consecutive chronic total occlusion (CTO) lesions with pre-procedural coronary computed tomography angiography (CCTA) data; it established a simple and accurate CCTA model for predicting successful guidewire crossing within 30 min through CTO. The proposed CCTA scoring system does not suffer from the limitations of conventional angiography and thus has the potential to exceed the discriminatory performance of the previously validated angiographic models. Clinicians may find the CT-RECTOR score particularly useful for predicting the time-efficient percutaneous revascularization and thus difficulty grading in CTO. It is recognized that the multiple episodes of supply ischemia that occur with balloon inflations during percutaneous coronary interventions result in stunning and cumulative left ventricular dysfunction. The cardioprotective properties of glucagon-like peptide-1 (GLP-1) may have potential as a therapeutic adjunct to support the heart during myocardial ischemia. However, mechanisms remain unclear. This study was therefore undertaken to provide some mechanistic insights into GLP-1-related cardioprotection. Specifically, the authors sought to determine whether pre-treatment with intravenous GLP-1(7-36) amide, commenced before an ischemic insult, protected the heart during percutaneous coronary intervention and whether it was associated with changes in the myocardial use of glucose. 
